AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22052104 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin 4% solution administered intraperitoneally
Number of subjects: 181
Study 22052104 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 181
Study 22052104 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin 4% solution
Number of subjects: 181
Study 19605605 — intervention group
Group type: EXPERIMENTAL
Intervention: Single patient trials (SPTs) for commonly employed treatments in palliative care, specific drugs not mentioned.
Number of subjects: 0
Study 19605605 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17192355 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations from the American Diabetes Association (ADA) for cardiovascular risk factors in patients with diabetes
Number of subjects: 0
Study 17192355 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations from the American Heart Association (AHA) for cardiovascular disease prevention
Number of subjects: 0
Study 17192355 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonization of AHA and ADA recommendations
Number of subjects: 0
Study 16301258 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated CVC
Number of subjects: 275
Study 16301258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-silversulfadiazine (CH-SS) CVC
Number of subjects: 275
Study 16301258 — intervention group
Group type: COMPARATOR
Intervention: Standard CVC
Number of subjects: 275
Study 11914985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia at 434 MHz
Number of subjects: 44
Study 11914985 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound
Number of subjects: 44
Study 10099044 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg famotidine
Number of subjects: 24
Study 10099044 — intervention group
Group type: COMPARATOR
Intervention: 200 mg cimetidine
Number of subjects: 24
Study 10099044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10150322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (2 g/1 g)
Number of subjects: 53
Study 10150322 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g)
Number of subjects: 53
Study 1967947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.01 mg kg‐1 as a priming dose followed by 0.1 mg kg‐1 intubation dose
Number of subjects: 32
Study 1967947 — intervention group
Group type: COMPARATOR
Intervention: No priming dose of vecuronium
Number of subjects: 32
Study 7312521 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% catch-trials
Number of subjects: 33
Study 7312521 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% catch-trials
Number of subjects: 33
Study 7312521 — intervention group
Group type: COMPARATOR
Intervention: No catch-trials
Number of subjects: 33
Study 31757262 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/day galantamine
Number of subjects: 93
Study 31757262 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/day galantamine
Number of subjects: 93
Study 31757262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 29079603 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoCPAP with SensAwake
Number of subjects: 48
Study 29079603 — intervention group
Group type: COMPARATOR
Intervention: Conventional AutoCPAP
Number of subjects: 48
Study 26138419 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐21‐5p overexpression group (adenovirus+0.5 mmol/L H2O2)
Number of subjects: 4
Study 26138419 — intervention group
Group type: COMPARATOR
Intervention: H2O2 challenge group (0.5 mmol/L H2O2)
Number of subjects: 4
Study 26138419 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐21‐5p negative transfection group (adenovirus void+0.5 mmol/L H2O2)
Number of subjects: 4
Study 26138419 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐21‐5p overexpression group
Number of subjects: 4
Study 23591949 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 24
Study 23591949 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching plus hip/spine disassociation exercises
Number of subjects: 24
Study 23591949 — intervention group
Group type: EXPERIMENTAL
Intervention: Core endurance
Number of subjects: 24
Study 23591949 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 23591949 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 24
Study 21640520 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam pelvic radiotherapy (EBRT)
Number of subjects: 714
Study 21640520 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (NAT)
Number of subjects: 714
Study 21640520 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT
Number of subjects: 714
Study 21640520 — intervention group
Group type: COMPARATOR
Intervention: NAT
Number of subjects: 714
Study 19144730 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge meal
Number of subjects: 177
Study 19144730 — intervention group
Group type: COMPARATOR
Intervention: Normal meal
Number of subjects: 177
Study 19144730 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC participants
Number of subjects: 177
Study 19144730 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge meal (overweight and obese girls with LOC)
Number of subjects: 177
Study 18667139 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin initiation in patients with T2DM
Number of subjects: 0
Study 18667139 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term lifestyle modifications
Number of subjects: 0
Study 18667139 — intervention group
Group type: EXPERIMENTAL
Intervention: Family physician's role
Number of subjects: 0
Study 15852734 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or chemoradiation followed by surgery
Number of subjects: 0
Study 15852734 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiation
Number of subjects: 0
Study 15852734 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 11226106 — intervention group
Group type: EXPERIMENTAL
Intervention: LR Before group (12 mL/kg of LR solution within 20 min before spinal anesthesia)
Number of subjects: 75
Study 11226106 — intervention group
Group type: EXPERIMENTAL
Intervention: LR After group (12 mL/kg of LR solution within 20 min starting immediately after spinal anesthesia)
Number of subjects: 75
Study 11226106 — intervention group
Group type: COMPARATOR
Intervention: No Infusion group (no LR solution given)
Number of subjects: 75
Study 9692270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT) plus disulfiram
Number of subjects: 122
Study 9692270 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation (TSF) plus disulfiram
Number of subjects: 122
Study 9692270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Management (CM) plus disulfiram
Number of subjects: 122
Study 9692270 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT) plus no medication
Number of subjects: 122
Study 9692270 — intervention group
Group type: COMPARATOR
Intervention: Twelve Step Facilitation (TSF) plus no medication
Number of subjects: 122
Study 8168892 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated open extremity fractures
Number of subjects: 41
Study 8168892 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of patients with open fractures in studies
Number of subjects: 41
Study 3300140 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 3300140 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 24
Study 31845341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionized hypocalcaemia
Number of subjects: 226
Study 29782968 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback session aimed at increasing deoxygenated hemoglobin (deoxy-Hb)
Number of subjects: 48
Study 29782968 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback session aimed at decreasing oxygenated hemoglobin (oxy-Hb)
Number of subjects: 48
Study 29782968 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback session
Number of subjects: 48
Study 28836796 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT (12-14 sessions)
Number of subjects: 115
Study 28836796 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Entry Training (TEnT) (4-6 sessions)
Number of subjects: 115
Study 28836796 — intervention group
Group type: COMPARATOR
Intervention: Al-Anon/Nar-Anon Facilitation (ANF) (12-14 sessions)
Number of subjects: 115
Study 26057863 — intervention group
Group type: EXPERIMENTAL
Intervention: AT20-KLH vaccination
Number of subjects: 10
Study 22336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag powder for oral suspension (PfOS) 25 mg administered fasted
Number of subjects: 40
Study 22336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag PfOS with a high‐calcium meal
Number of subjects: 40
Study 22336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag PfOS 2 hours after a high‐calcium meal
Number of subjects: 40
Study 22336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag PfOS 2 hours before a high‐calcium meal
Number of subjects: 40
Study 22336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag PfOS
Number of subjects: 40
Study 22336488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 40
Study 20171661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon juice
Number of subjects: 24
Study 20171661 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fluid intake
Number of subjects: 24
Study 20171661 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 24
Study 17337249 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 40
Study 17337249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 40
Study 17337249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16324542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐Atracurium (muscle relaxant)
Number of subjects: 13
Study 16324542 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxant
Number of subjects: 13
Study 12218279 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% chlorhexidine varnish (Chlorzoin)
Number of subjects: 75
Study 12218279 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 75
Study 9484761 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 with cyclosporine from day of transplantation (group A)
Number of subjects: 51
Study 9484761 — intervention group
Group type: COMPARATOR
Intervention: BT563 with cyclosporine starting on day 3 (group B)
Number of subjects: 51
Study 9484761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups A and B
Number of subjects: 51
Study 9484761 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 presence during acute rejection
Number of subjects: 51
Study 7707139 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a 3-month international study program
Number of subjects: 28
Study 7707139 — intervention group
Group type: COMPARATOR
Intervention: Not participating in the international study program
Number of subjects: 28
Study 2709216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1,000 mg administered 30 minutes preoperatively
Number of subjects: 20
Study 2709216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1,000 mg administered 30 minutes postoperatively
Number of subjects: 20
Study 75692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic hyperosmolar urea and 5 mg. of prostaglandin F2alpha (PGF2alpha)
Number of subjects: 150
Study 75692 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic hyperosmolar urea alone
Number of subjects: 150
Study 75692 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic hyperosmolar urea and 10 mg. of prostaglandin F2alpha
Number of subjects: 150
Study 30615117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab plus corticosteroids
Number of subjects: 0
Study 30615117 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus corticosteroids
Number of subjects: 0
Study 30615117 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab alone
Number of subjects: 0
Study 30615117 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 29486753 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO-5A based comprehensive tobacco control program (adapted 5A group counseling supported by social media and traditional health education)
Number of subjects: 315
Study 29486753 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 315
Study 27581505 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting group (n = 143)
Number of subjects: 545
Study 27581505 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal checking group (n = 132)
Number of subjects: 545
Study 27581505 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 270)
Number of subjects: 545
Study 27581505 — intervention group
Group type: COMPARATOR
Intervention: All groups (overall figures)
Number of subjects: 545
Study 27581505 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 545
Study 27581505 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for employed women
Number of subjects: 545
Study 27581505 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for unemployed men
Number of subjects: 545
Study 24667509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (8-hour case-based curriculum focused on six mentoring competencies)
Number of subjects: 283
Study 24667509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 283
Study 24667509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study 22964475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (800 IU/day)
Number of subjects: 92
Study 22964475 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2 g/day)
Number of subjects: 92
Study 22964475 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2 g/day) and Vitamin D3 (800 IU/day)
Number of subjects: 92
Study 22964475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19997906 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (cognitive-enhancing drug)
Number of subjects: 0
Study 19997906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19997906 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 0
Study 18073061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (therapeutic group)
Number of subjects: 13
Study 18073061 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (preventive therapeutic group)
Number of subjects: 13
Study 16118574 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) training for 8 weeks, 32 sessions of isometric EMS
Number of subjects: 20
Study 16118574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS training)
Number of subjects: 20
Study 11872516 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused individual psychotherapy (up to 30 sessions)
Number of subjects: 71
Study 11872516 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group therapy (up to 18 sessions)
Number of subjects: 71
Study 10603440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 0
Study 10603440 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 8682011 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 214
Study 8682011 — intervention group
Group type: COMPARATOR
Intervention: Control (non fibrinolytic medical therapy)
Number of subjects: 214
Study 2233906 — intervention group
Group type: EXPERIMENTAL
Intervention: H. influenzae type b polysaccharide‐diphtheria toxoid conjugate vaccine (PRP‐D)
Number of subjects: 2102
Study 2233906 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 2102
Study 2233906 — intervention group
Group type: EXPERIMENTAL
Intervention: H. influenzae type b polysaccharide‐diphtheria toxoid conjugate vaccine (PRP‐D) after three doses
Number of subjects: 2102
Study 582880 — intervention group
Group type: EXPERIMENTAL
Intervention: Homatropine methylbromide plus phenobarbital in a 20% alcohol solution
Number of subjects: 97
Study 582880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 30953544 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 2-mA tDCS for 20 min once a day for 10 consecutive weekdays
Number of subjects: 70
Study 30953544 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 20 min once a day for 10 consecutive weekdays
Number of subjects: 70
Study 28165268 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 85
Study 25843243 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp with 270 mgI/mL iodixanol
Number of subjects: 231
Study 25843243 — intervention group
Group type: COMPARATOR
Intervention: 120-kVp filtered back projection
Number of subjects: 231
Study 23648282 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation (TBS)
Number of subjects: 0
Study 23648282 — intervention group
Group type: COMPARATOR
Intervention: 1Hz repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study 21252738 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration for 12 hours after membrane rupture
Number of subjects: 1347
Study 21252738 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 1347
Study 19723905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoprostenol (Flolan)
Number of subjects: 102
Study 17335723 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 1188
Study 15855569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (7.5 mg/day)
Number of subjects: 372
Study 15855569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 15855569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (7.5 mg/day) in subgroup with IAA levels > or =80 nU/ml (n = 263)
Number of subjects: 372
Study 15855569 — intervention group
Group type: COMPARATOR
Intervention: Placebo in subgroup with IAA levels > or =80 nU/ml (n = 263)
Number of subjects: 372
Study 12477321 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 747
Study 12477321 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone/Cefpodoxime
Number of subjects: 747
Study 9859998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5- to 1-minute MMC
Number of subjects: 124
Study 9859998 — intervention group
Group type: EXPERIMENTAL
Intervention: 3- to 5-minute MMC
Number of subjects: 124
Study 9859998 — intervention group
Group type: COMPARATOR
Intervention: No MMC
Number of subjects: 124
Study 10150674 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser etching (CO2 laser)
Number of subjects: 0
Study 10150674 — intervention group
Group type: COMPARATOR
Intervention: Acid etching (orthophosphoric acid)
Number of subjects: 0
Study 2598585 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine iothalamate (Conray 280) with adrenaline
Number of subjects: 0
Study 2598585 — intervention group
Group type: COMPARATOR
Intervention: Meglumine iothalamate (Conray 280) without adrenaline
Number of subjects: 0
Study 2598585 — intervention group
Group type: COMPARATOR
Intervention: Sodium meglumine ioxaglate (Hexabrix 320) without adrenaline
Number of subjects: 0
Study 2598585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meglumine ioxaglate (Hexabrix 320) with adrenaline
Number of subjects: 0
Study 788655 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (Ampicillin)
Number of subjects: 58
Study 788655 — intervention group
Group type: COMPARATOR
Intervention: Non-antibiotic treatment
Number of subjects: 58
Study 31974806 — intervention group
Group type: EXPERIMENTAL
Intervention: RW program delivered during home visit
Number of subjects: 119
Study 31974806 — intervention group
Group type: EXPERIMENTAL
Intervention: RW program delivered in group presentation followed by home visit
Number of subjects: 119
Study 31974806 — intervention group
Group type: EXPERIMENTAL
Intervention: RW program (both delivery methods)
Number of subjects: 119
Study 31605521 — intervention group
Group type: EXPERIMENTAL
Intervention: Load blinding (BLI)
Number of subjects: 32
Study 31605521 — intervention group
Group type: COMPARATOR
Intervention: Load nonblinding (nBLI)
Number of subjects: 32
Study 27590273 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy with fluoxetine
Number of subjects: 0
Study 27590273 — intervention group
Group type: COMPARATOR
Intervention: Referral to community mental health treatment
Number of subjects: 0
Study 25807800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested anti-rotavirus IgY
Number of subjects: 100
Study 25807800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 23088748 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin therapy
Number of subjects: 58
Study 23088748 — intervention group
Group type: COMPARATOR
Intervention: Intravenous insulin therapy
Number of subjects: 58
Study 21713745 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 5mg/kg intravenously after induction of anesthesia
Number of subjects: 120
Study 21713745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 120
Study 21713745 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 120
Study 19702616 — intervention group
Group type: EXPERIMENTAL
Intervention: Full bedrail use
Number of subjects: 1092
Study 19702616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' description of patients as immobile and very or slightly confused
Number of subjects: 1092
Study 19702616 — intervention group
Group type: COMPARATOR
Intervention: Older patients
Number of subjects: 1092